AlyveRx review
Tirzepatide comes as an injection and as needle-free sublingual drops, and the two are priced as different products.
The verdict
AlyveRx publishes $183 a month for a compounded semaglutide injection and $283 for a compounded tirzepatide injection. Needle-free sublingual tirzepatide drops are a separate product at $249. AlyveRx states the rate is lower on longer plans and holds at every dose.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- Dose pricing
- Flat across doses
- From
- From $183/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
AlyveRx sells compounded injections of both molecules. Tirzepatide is also sold as sublingual drops. The route differs between them, which the pages state rather than leave to be assumed.
Who writes the prescription, and what do they see?
A prescription precedes shipping. The pages describe the route and the billing rather than the clinician. What the intake asks is not published.
Naming the route on each line is the disclosure. A reader comparing the $249 drops against another seller's tirzepatide injection is comparing two different products. AlyveRx says which is which.
What happens when the dose goes up?
The rate is stated to hold at every dose. Longer plans are said to lower it, without the figures being published. So the dose question is answered and the term question is not.
What the price includes
$183 is the monthly semaglutide injection rate. Six months at it is $1,098. The tirzepatide injection is $283, or $1,698 over six months. The drops are $249. Whether a drop at $249 is dearer than an injection is not a question a price answers. The milligrams do not read across. What longer plans cost is not published.
What it claims, and what it cites
Both lines are compounded. The FDA does not review them before dispensing. Sublingual drops and a weekly injection are not interchangeable milligram for milligram, and no absorption data is published for the drop route.
Where it holds up, and where it does not
- Strength: The route is named on each line
- Strength: Rate stated to hold at every dose
- Strength: All three figures published without an intake
- Limitation: Longer-plan rates are not published
- Limitation: No absorption data for the drops
- Limitation: Only two molecules are offered
- Limitation: No state coverage list is recorded
What the evidence says about this kind of treatment
The assessment above is about AlyveRx. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who wants a needle-free route named as such rather than implied.
- Wrong for
- A reader comparing the drops against an injection on milligrams.
The evidence behind what AlyveRx prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How AlyveRx compares
| Seller | Who it suits | Go |
|---|---|---|
 Actin | A reader weighing term lengths who will confirm the price at each dose step | See Actin → |
| Bayan Health | A reader weighing an injection against an oral preparation at one seller, where both routes carry the same monthly figure. | See Bayan Health → |
 Idgie Health | A reader who wants a seller to say plainly that a microdose is an off-label use before taking a payment for one. | See Idgie Health → |
More GLP-1 telehealth sellers reviews: Citizen MedsClayaClinic SecretClume HealthCLYR HealthCoivas
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Are the drops equivalent to an injection?
- Not established. Sublingual and injected milligrams do not read across, and AlyveRx publishes no absorption data for the drop route.
- What do longer plans cost?
- Not published. AlyveRx states the rate is lower on longer plans without giving the figures.
- Does the price rise with the dose?
- AlyveRx states it does not, on both lines.
- Is AlyveRx expensive compared with other GLP-1 telehealth sellers?
- AlyveRx publishes a starting figure of $183/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts AlyveRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.